Megan R. Reed

Postdoc

University of Arkansas for Medical Sciences

postdoc

15 h-index 45 pubs 645 cited

Research Areas

CAR-T cell therapy research Cancer Treatment and Pharmacology Cancer-related molecular mechanisms research Neuroscience and Neuropharmacology Research Molecular Biology Techniques and Applications Glioma Diagnosis and Treatment Cancer Immunotherapy and Biomarkers Advanced biosensing and bioanalysis techniques

Links

ORCID Research Group

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Megan R. Reed's research investigates novel therapeutic strategies for glioblastoma, a challenging form of brain cancer. Her work has explored the potential of CAR T-cell therapies, a form of immunotherapy, in treating solid tumors, including brain tumors. Reed also studies the anti-glioblastoma activity of specific compounds, such as monensin and its analogs, utilizing organoid models to assess their efficacy. Her research extends to functional precision medicine, developing pipelines that combine comparative transcriptomics and tumor organoid modeling to identify personalized treatment approaches for glioblastoma. Additionally, Reed has contributed to the field of synthetic biology, focusing on the genetic encoding of photocaged amino acids for light-controlled protein activity and the development of genetically encoded biosensors for antibiotic biosynthesis. Her scholarship metrics include an h-index of 15, with 45 total publications and 645 citations. She has collaborated extensively with researchers at the University of Arkansas for Medical Sciences, including Robert L. Eoff, Billie Heflin, Brian Koss, and Daniel Fil.

Metrics

h-index: 15
Publications: 45
Citations: 645

Selected Publications

685 EZH2 inhibition impairs CD8+ CAR-T cell persistence (2025) DOI
691 ATF6 activation promotes ICB response in melanoma (2025) DOI
Evaluation of the Activity of Monensin and Its Analogs for Modulation of Stem-like Cell Functionality in 2D and 3D Breast Cancer Models (2025) DOI
Monensin and Its Analogs Exhibit Activity Against Breast Cancer Stem-Like Cells in an Organoid Model (2025) DOI
EZH2 loss during metabolic stress drives restoration of MHC class I machinery in melanoma (2025) DOI
1132 Enhancing melanoma therapy efficacy by protecting EZH2 activity in T cells (2024) DOI
538 ATF6 activation in melanoma promotes anti-tumor immunity and improves ICB therapy response (2024) DOI
Abstract 1333 DNA polymerase kappa (Pol k) promotes replication gap suppression by preventing PrimPol mediated repriming and safeguards genomic stability in Glioblastoma Multiforme (GBM) (2024) DOI
Abstract 584: Synergistic action of ATF6 and EZH2 in sensing metabolic stress to boost anti-tumor immunity (2024) DOI
536 EZH2 senses metabolic stress to restore MHC-I antigen presentation and ICB response in metastatic melanoma (2023) DOI
Abstract LB041: EZH2 and ATF6 sense metabolic stress to balance MHC class I antigen presentation in melanoma (2023) DOI
CAR-T Therapies in Solid Tumors: Opportunities and Challenges (2023) DOI
CAR T-cells to treat brain tumors (2023) DOI
Anti-glioblastoma activity of monensin and its analogs in an organoid model of cancer (2022) DOI
Monensin and its analogues show anti‐glioblastoma activity in an organoid model of cancer (2022) DOI